MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors - Summary - MDSpire

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication

  • May 7, 2026

  • 4 min

Share

Objective:

To evaluate the safety and efficacy of SurVaxM in combination with temozolomide in patients with progressing metastatic neuroendocrine tumors (NETs).

Key Findings:
  • SurVaxM is a peptide vaccine targeting the protein survivin, which is expressed in approximately 52% of NET specimens.
  • Phase 1 study showed SurVaxM was well tolerated and generated measurable immune responses.
  • The incidence of NETs has increased significantly, with about 28,000 new cases diagnosed annually in the U.S.
Interpretation:

The trial aims to provide new treatment options for NET patients, particularly those with limited therapies after first-line treatment.

Limitations:
  • The trial's outcomes are yet to be determined as it is in the early stages.
  • Immunotherapy has shown limited efficacy in NETs historically.
Conclusion:

The phase 2 trial represents a significant step in exploring new immunologic targets for treating metastatic NETs, building on promising phase 1 results.

Original Source(s)

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

  • May 7, 2026

Related Content

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min
Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

  • June 24, 2026

  • 1 min
ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min